Results 151 to 160 of about 12,467 (245)

L467F;F508del Complex Allele in a Heterozygous State with CFTRdele2,3: What to Expect from CFTR Modulators? [PDF]

Int J Mol Sci
Kondratyeva E, Efremova A, Melyanovskaya Y, Krasnova M, Milovanov M, Shchagina O, Stepanova A, Voronkova A, Sherman V, Kutsev S, Goldshtein D.   +10 more
europepmc   +1 more source

Corrigendum: Effect of elexacaftor-tezacaftor-ivacaftor on nasal potential difference and lung function in Phe508del rats [PDF]

Nicole Reyne, Patricia Cmielewski, Alexandra McCarron, Ronan Smith, Elena K. Schneider‐Futschik, Nina Eikelis, Piraveen Pirakalathanan, David Parsons, Martin Donnelley   +8 more
openalex   +1 more source

Impact of Elexacaftor-Tezacaftor-Ivacaftor on Gastrointestinal Symptoms, Intestinal Ultrasound, and Pancreatic Stiffness in Cystic Fibrosis. [PDF]

Clin Transl Gastroenterol
Fraquelli M, Piagnani A, Corti F, Lanfranchi C, Casazza G, Colombo C.   +5 more
europepmc   +1 more source

Transcriptomic Responses to Ivacaftor and Prediction of Ivacaftor Clinical Responsiveness

, 2019
Tao Sun, Zhe Sun, Yale Jiang, Annabel A. Ferguson, Joseph M. Pilewski, Jay K. Kolls, Wei Chen, Kong Chen   +7 more
openalex   +2 more sources

233 Magnetic resonance imaging metrics in cystic fibrosis before and after elexacaftor/tezacaftor/ivacaftor—the Gut Imaging for Function and Transit in Cystic Fibrosis 3 Study

, 2022
A. Yule, C. Ng, N. Dellschaft, C. Hoad, I. Stewart, Luca Marciani, P. Gowland, G. Major, R. Spiller, A. Smyth   +9 more
openalex   +1 more source

Ivacaftor – le premier médicament pour le traitement causal de la mucoviscidose [PDF]

, 2014
Nina Lenherr‐Taube, Linn Krueger, Marco Lurà, Philipp Latzin, Carmen Casaulta, Jürg Hammer   +5 more
openalex   +1 more source

Assessment of efficacy and tolerability of elexacaftor-tezacaftor-ivacaftor in an observational cohort study of "aged" people with cystic fibrosis. [PDF]

Ther Adv Respir Dis
Blankenship S, Flueckiger BV, Caleb G, Bailey J, Baker E, Garcia B, Krick S.   +6 more
europepmc   +1 more source

Cystic Fibrosis and CFTR Modulators: The Impact on Bone Density, Muscle Mass and Strength in Children and Young Adolescents. [PDF]

Children (Basel)
Iordanidou K, Karakousis ND, Hatziagorou E, Chrysochoou EA, Galogavrou M, Sopiadou A, Papagianni M.   +6 more
europepmc   +1 more source

Safety, Pharmacokinetics, and Pharmacodynamics of Lumacaftor/Ivacaftor Combination Therapy in Children Aged 2-5 Years with Cystic Fibrosis Homozygous for <i> F508del-CFTR</i>: An Open-Label Phase 3 Study

, 2018
John McNamara, Susanna A. McColley, Gautham Marigowda, Fang Liu, Simon Tian, Caroline A. Owen, David Stiles, Chonghua Li, David Waltz, Linda T. Wang, Gregory S. Sawicki   +10 more
openalex   +1 more source

Elexacaftor-tezacaftor-ivacaftor enhances first-phase insulin secretion and improves glucose control in cystic fibrosis. [PDF]

Endocr Connect
Edlund A, Lindberg U, Fagher K, Påhlman LI.   +3 more
europepmc   +1 more source